Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -15.38% | -16.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.34% | -10.17% | |||
| Operating Income | -9.34% | 10.17% | |||
| Income Before Tax | -10.19% | 9.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.19% | 9.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.19% | 9.11% | |||
| EBIT | -9.34% | 10.17% | |||
| EBITDA | -9.48% | 10.27% | |||
| EPS Basic | -8.52% | 11.02% | |||
| Normalized Basic EPS | -8.53% | 11.03% | |||
| EPS Diluted | -8.52% | 11.75% | |||
| Normalized Diluted EPS | -8.53% | 11.03% | |||
| Average Basic Shares Outstanding | 1.53% | 2.15% | |||
| Average Diluted Shares Outstanding | 1.53% | 2.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||